Fesoterodine
- Generic Name
- Fesoterodine
- Brand Names
- Toviaz
- Drug Type
- Small Molecule
- Chemical Formula
- C26H37NO3
- CAS Number
- 286930-02-7
- Unique Ingredient Identifier
- 621G617227
- Background
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
- Indication
适用于治疗急迫性尿失禁和膀胱过度活动综合征患者的尿频、尿急、尿失禁或所有这些症状组合。
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 774
- Registration Number
- NCT00943735
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 566
- Registration Number
- NCT00928070
- Locations
- 🇺🇸
Pfizer Investigational Site, Spokane, Washington, United States
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 963
- Registration Number
- NCT00911937
- Locations
- 🇺🇸
Pfizer Investigational Site, Menomonee Falls, Wisconsin, United States
The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
- Conditions
- Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT00911235
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00902187
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
A Bioequivalence Study Of 8 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT00902681
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Toviaz Post Marketing Surveillance Study
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3000
- Registration Number
- NCT00879398
- Locations
- 🇰🇷
Hankook General Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷Lee Urology Clinic, Namyangju-si, Gyeonggi-do, Korea, Republic of
🇰🇷Moa gynecology, Nonsan-si, Chungcheongnam-do, Korea, Republic of
Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
- Conditions
- Urge Urinary IncontinenceOveractive Bladder
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 645
- Registration Number
- NCT00862745
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸University of Texas Health Science Center San Antonio, San Antonio, Texas, United States
🇺🇸University of Virginia-Women's Midlife Health Center, Charlottesville, Virginia, United States
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
- Conditions
- Overactive BladderNeurogenic Detrusor Overactivity
- Interventions
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2011-11-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT00857896
- Locations
- 🇺🇸
Pfizer Investigational Site, Liberty Township, Ohio, United States
Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00832650
- Locations
- 🇺🇸
Pfizer Investigational Site, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.